Black Diamond Therapeutics I (BDTX) Institutional Ownership Tracker (Q2 2026)

BDTX ranks #4596 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

100 institutions disclose a position in BDTX, but none treat it as a major bet — even NEA Management Company, LLC, its most concentrated holder, allocates just 0.5% of its own portfolio to it.

BlackRock has added to its BDTX position for two straight quarters, increasing it by $5.1M to reach $7.2M today.

T. Rowe Price has trimmed its BDTX position for two straight quarters, cutting it by $18.3M while still holding $7.5M.

BDTX is up 4.9% today, and institutions have been net buyers of $5.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

BDTX reported a net loss of $42.6M over the trailing twelve months.

• Not yet profitable — net loss of $42.6M over the trailing twelve months
• Net income declined year over year, from $14.4M to -$42.6M
• Generated $29.6M in positive operating cash flow
• Current ratio of 8.42x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.27x equity — within a conventional range